TY  - JOUR
A1  - Wacker, Matthias
T1  - Challenges in the drug release testing of next-generation nanomedicines – What do we know?
T2  - Materials Today: Proceedings
N2  - Despite all advances in drug delivery, the limitations of the analytical technologies involved in the characterization of next-generation nanomedicines are still impeding further progress of an emerging market. Discriminating between different formulations and batches, drug release is one of the most important quality criteria in development and quality control of pharmaceutics. Unfortunately, there are only few methods available to sensitively measure this important parameter for nanosized carriers. With the development of the dispersion releaser (DR) technology our group has set up a dialysis-based technique that was tested with a number of nanocarrier and nanocrystal formulations such as liposomes and polymeric nanoparticles. By supporting formulation development with a more reliable methodology to assess the drug release from nanosized carriers, a first step has been made to improve future products.
KW  - Nanocarriers
KW  - QbD
KW  - Release testing
KW  - Dissolution nanoparticles
KW  - Liposomes
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/77353
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-773539
SN  - 2214-7853
VL  - 4
IS  - Supplement 2
SP  - S214
EP  - S217
PB  - Elsevier
CY  - Amsterdam
ER  -